IDXG

INTERPACE BIOSCIENCES, INC.

OTC · Surgical & Medical Instruments & Apparatus · Inc. DE · CIK 0001054102
$1.60 -3.03%
Vol
SEC Reports1
Exchange OTC·Sector Surgical & Medical Instruments & Apparatus·Inc. DE·CIK 0001054102·Prev Close $1.65

Recent Activity

May 6, 2026 earnings_calendar
IDXG Q1 2026 Earnings Scheduled — 2026-05-06
Apr 21, 2026 SEC
Interpace Biosciences reported full-year 2025 revenue of $38.7 million and income from continuing operations of $25.0 mi
8-K — Impact 6/10
Jan 20, 2026 Insider
1315 Capital II, L.P. acquired 9,405,941 shares
10%+ Owner @ $2.02 ($19.0M)
Jan 20, 2026 Insider
1315 Capital II, L.P. disposed of 19,000 shares
10%+ Owner
Jan 20, 2026 Insider
Ampersand 2018 Limited Partnership acquired 13,861,386 shares
10%+ Owner @ $2.02 ($28.0M)

Analyst Ratings

Historical distribution0% buy · 6 analysts · last covering-analyst action Nov 2021
0Strong Buy
0Buy
3Hold
1Sell
2Strong Sell
Historical Analyst Actions
DateFirmActionRating
Nov 17, 2021 HC Wainwright & Co. DOWNGRADE Buy → Neutral
Apr 9, 2021 HC Wainwright & Co. MAINTAIN Buy
Jan 25, 2021 HC Wainwright & Co. MAINTAIN Buy
Oct 22, 2020 HC Wainwright & Co. MAINTAIN Buy
Jun 26, 2020 HC Wainwright & Co. MAINTAIN Buy

Recent Insider Trades

DateInsiderTypeValue
Jan 20, 20261315 CapitalC$19.0M
Jan 20, 20261315 CapitalC$0.00
Jan 20, 2026Ampersand 2018C$28.0M
Jan 20, 2026Ampersand 2018C$0.00

No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.

2 unique insiders with 4 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
Jan 20, 20261315 Capital II, L.P.10%+ OwnerCONVERT9,405,941$2.02$19.0M
Jan 20, 20261315 Capital II, L.P.10%+ OwnerCONVERT19,000
Jan 20, 2026Ampersand 2018 Limited Partnership10%+ OwnerCONVERT13,861,386$2.02$28.0M
Jan 20, 2026Ampersand 2018 Limited Partnership10%+ OwnerCONVERT28,000
1 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 0 neutral. Avg impact: 6.0/10.

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Historical analyst distribution (last covering-analyst action Nov 2021): 0% buy across 6 analysts — 0 strong buy, 0 buy, 3 hold, 1 sell, 2 strong sell. No current recommendation available.

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
$0.00 $0.00 $0.00 $0.0B
Next Q
$0.00 $0.00 $0.00 $0.0B
Current FY
2025-12-31
$0.00 $0.00 $0.00 $0.0B
Next FY
$0.00 $0.00 $0.00 $0.0B
3 analyst firms have rated this stock: 0 upgrades, 1 downgrades, 1 initiations.

Historical Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
Nov 17, 2021 HC Wainwright & Co. DOWNGRADE Buy Neutral
Apr 9, 2021 HC Wainwright & Co. MAINTAIN Buy
Jan 25, 2021 HC Wainwright & Co. MAINTAIN Buy
Oct 22, 2020 HC Wainwright & Co. MAINTAIN Buy
Jun 26, 2020 HC Wainwright & Co. MAINTAIN Buy
Apr 23, 2020 HC Wainwright & Co. MAINTAIN Buy
Apr 15, 2020 Janney Montgomery Scott INITIATE Buy
Jan 16, 2020 Oppenheimer MAINTAIN Outperform

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Apr 1, 2023003120%
Mar 1, 2023003120%
Feb 1, 2023003120%
Jan 1, 2023003120%
Strong BuyBuyHoldSellStrong Sell

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

May 6, 2026
earnings_calendar
IDXG Q1 2026 Earnings Scheduled — 2026-05-06
Mar 30, 2026
earnings_calendar
IDXG Q4 2025 Earnings Scheduled — 2026-03-30